GlobalData on MSN19h
Alltrna plans to tackle rare diseases using tRNA-based therapies
Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...
precisionmedicineonline11h
CHMP Recommends Vertex's Kaftrio, Kalydeco Combo for Additional Cystic Fibrosis Patients
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
Vertex Pharmaceuticals gets CHMP opinion recommending Kaftrio label expansion
Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market
The stock's rise snapped a four-day losing streak.
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug
Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...
JD Supra11h
Life Sciences Under the Microscope: Key 2024 Takeaways and What’s Ahead for 2025
The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...